Zenas BioPharma Announces Publication of Phase 2 Study of Obexelimab, an Investigational Treatment for IgG4-Related Disease (IgG4-RD), in The Lancet Rheumatology
Globe Newswire1-08-2023, 19:23
Maha Energy completes the sale of Maha Energy Brasil to 1-03-2023, 00:53